Bellerophon Therapeutics LLC, (Hampton, NJ, USA) is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Bellerophon acquired exclusive worldwide rights to develop and commercialize the INOpulse programs in PAH, PH-COPD and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) from Ikaria, Inc. in February 2014 as part of Ikaria's spin-out of certain of its research and development assets and subsidiaries. Bellerophon has an exclusive worldwide license to BCM from BioLineRx Ltd.